Lanly Bioscience
Current position:
Xenograft tumor model

In vivo pharmacology

Xenograft tumor model


In tumor-related basic research and application research, there are many different models used to simulate tumor occurrence, development, metastasis, and evaluation of the therapeutic effect of new molecules. Among them, the most widely used in the drug development process is the human cancer xenografts model (Human cancer xenografts). The basic process of xenograft tumor model is to inoculate human-derived tumor cells into immunodeficient mice. After the tumor grows to a certain size (usually 100-250 mm3), mice with appropriate tumor size are selected for group administration. Among them, the human tumor cells can be isolated and cultured tumor cell lines (Cell-Derived Xenografts, CDX), or tumor tissue masses (Patient-Derived Xenografts, PDX). The selection of immunodeficiency mouse strains has a crucial influence on the success rate of modeling and experimental quality. Commonly used immunodeficiency mouse strains include BALB/c Nude, NU/NU, NOD SCID, NSG, etc. In addition, there are many options for the site of vaccination. The most common one is subcutaneous vaccination. Other vaccination methods include in situ vaccination, intraperitoneal vaccination and intravenous vaccination.

Although the CDX model cannot well simulate the occurrence, development and evolution of tumors in the human body, it has many advantages, which makes it widely used in the preclinical pharmacodynamic evaluation of drugs. Its advantages include: 1. Fast modeling, good repeatability, and stable data quality; 2. Generally, the pharmacodynamic activity of the same tumor cell in vitro and in vivo is relatively correlated; 3. There are usually more tumor cell lines Historical research data and bioinformatics data help to understand the mechanism of action of drugs.

The models established and verified by Tuowei Biology are as follows:

Breast cancer model: HCC1954; MCF-7; BT474;

Colorectal cancer model: Colo205, HCT116, Ls174T, SW480, SW620; HT-29; KM12

Epidermal cancer model: A431;

Gastric cancer model: MKN45, NCI-N87; NUGC-3; MGC803

Glioma model: U87-MG; LN-229; U-118 MG

Leukemia model: MV-4-11; HL-60; HL-60(systemic); KARPAS-299; Raji; OCI-LY7

Liver cancer model: HCCLM3, Hep3B, SK-HEP-1; Hep G2;

Lung cancer model: Calu-6, NCI-H69, NCI-H460, NCI-H1975, NCI-H2228, HCC827, PC-9; A549; NCI-H526; NCI-H520; NCI-H441; NCI-H358

Lymphoma model: RS4:11; U2932; MOLT-4; Daudi;

Melanoma model: A375;

Oncogene model derived from Ba/F3: BAF3-NTRKA-G595R; BAF3-NTRKA-G667C; BAF3-NTRKC

Pancreatic cancer model: BON-1;

Ovarian cancer model: SK-OV-3; OVCAR3; IGROV-1

Prostate cancer model: LNCaP clone FGC; LNCaP

Scan the QR code to read on your phone

Contact Us

Time of issue:2021-03-22 16:58:53

Address:99 Mengxi Road, Shaxi Town, Taicang City, Jiangsu Province

Time of issue:2021-03-22 17:01:27

Lanly Bioscience
Scan code to browse

Time of issue:2021-03-22 16:00:55

Copyright:Lanly Bioscience Technology (Suzhou) Co., Ltd. | Copyright - 2021 All Rights Reserved.       苏ICP备2021010176号       Powered by

Time of issue:2021-03-22 16:01:26

©Lanly Bioscience Technology (Suzhou) Co., Ltd.
Powered by